Business Description
Editas Medicine is a Cambridge, Massachusetts-based company founded in 2013 that uses CRISPR technology to develop one-time genetic treatments for serious conditions such as high cholesterol, sickle cell disease, and beta thalassemia. Its most advanced treatment, EDIT-401, works by modifying genes to help the body better remove harmful cholesterol from the blood. The company is also working with Juno Therapeutics to create experimental cell-based treatments for cancer and autoimmune conditions.
